Last reviewed · How we verify
NCT04304417
The Role of Group Identity on the Community Integration of People With Severe Mental Disorder
trial in Bipolar Disorder in 70 participants. Completed in 1 April 2022.
1 April 2022
Quick facts
| Lead sponsor | Universidad Complutense de Madrid |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 17 February 2020 |
| Primary completion | 1 April 2022 |
| Estimated completion | 1 April 2022 |
| Sites | 1 location across Spain |
Conditions studied
- Bipolar Disorder — all drugs for Bipolar Disorder →
- Personality Disorders — all drugs for Personality Disorders →
- Psychotic Disorders — all drugs for Psychotic Disorders →
Sponsor
Universidad Complutense de Madrid — full company profile →
Who can join
18 and older, any sex, with Bipolar Disorder or Personality Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study analyzes which variables enhance or hinder community integration among people with severe mental disorder. Participants will complete a questionnaire to test our hypotheses: * Hypothesis 1: group identification predicts less self-dehumanization and self-stigma, and more empowerment, these in turn predict more community integration. * Hypothesis 2: the relationship between group identification and self-dehumanization and self-stigma is moderated by group value. * Hypothesis 3: when group identification is low, group identification predicts higher community integration, but this relationship is mediated by diagnosis concealment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04304417
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bipolar Disorder
Currently open trials in the same condition.
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT06911931 — Visual Perception in Schizophrenia · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07479758 — Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Out · recruiting
- NCT07140913 — A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur · Phase 3 · recruiting
Other Universidad Complutense de Madrid trials
Trials by the same sponsor.
- NCT07361848 — Long-Hold Yielding Isometric Exercise for Patellar Tendinopathy in Weightlifting Athletes · NA · not yet recruiting
- NCT07273006 — Percutaneous Electrical Nerve Stimulation As Alternative To Nerve Blocks In Anesthesia, Pain Medicine And Rehabilitation · Phase 4 · not yet recruiting
- NCT07527351 — ANALYSIS OF THE RELIABILITY AND VALIDITY OF LASER SPECKLE CONTRAST IMAGING · NA · recruiting
- NCT07484620 — Physical Activity and Fitness in Pediatric Inflammatory Bowel Disease · NA · not yet recruiting
- NCT07485400 — Aerobic Interval vs Continuous Training on Heart Rate-Power Decoupling in Ischemic Heart Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04304417 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Complutense de Madrid
- Last refreshed: 27 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04304417.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing